Previous 10 | Next 10 |
CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will participate in a fireside chat at the virtual ...
CAMBRIDGE, Mass. , May 28, 2020 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Par...
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will participate in a fireside chat at the Jefferies Vi...
Gainers: ACB +26.4% . SCVL +5.8% . PGNX +4.4% . EVLO +3.4% . OPRA +3.4% . More news on: Aurora Cannabis Inc., Shoe Carnival, Inc., Progenics Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Evelo Biosciences Inc (EVLO) Q1 2020 Results Conference Call May 11, 2020 8:30 AM ET Company Participants Jessica Cotrone - VP & Head of Communications Simba Gill - President and CEO Duncan McHale - Chief Medical Officer Mark Bodmer - Chief Scientific Officer and Presiden...
Evelo Biosciences (NASDAQ: EVLO ): Q1 GAAP EPS of -$0.71 beats by $0.04 . More news on: Evelo Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
–Submitted investigational new drug (IND) application for a Phase 2 trial of EDP1815 for COVID-19; data readout expected during 2H 2020– –Selected enteric capsule formulation of EDP1815 for Phase 2 dose ranging trial in psoriasis; trial initiation now expected in 3Q 202...
ION Geophysical (NYSE: IO ) +87% on Q1 results . More news on: ION Geophysical Corporation, Tetraphase Pharmaceuticals, Inc., Fastly, Inc., Stocks on the move, , Read more ...
Evelo Biosciences (NASDAQ: EVLO ) announces that investigators at Rutgers University and Robert Wood Johnson University Hospital have submitted an IND to the FDA for a Phase 2 clinical trial evaluating Evelo Biosciences' ( EVLO ) lead candidate EDP1815 in newly diagnosed COVID-19 patients....
—Early intervention in hospitalized patients could help prevent progression of disease— —EDP1815 has demonstrated favorable tolerability and anti-inflammatory activity in a prior clinical trial— —Data expected during 2H 2020— —Evelo Mana...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
OTCMKTS Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...